Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Picks Up Halo Genomics and BioSystem Development

Published: Monday, December 05, 2011
Last Updated: Monday, December 05, 2011
Bookmark and Share
The technologies company is expanding its life sciences business through the acquisition. Halo Genomics provides sample preparation technology for next-generation DNA sequencing, and BioSystem Development develops and manufactures sample prep solutions for drug R&D.

The acquisition of Halo, based in Uppsala, Sweden, is now final. The asset acquisition of BioSystem Development, headquartered in Madison, WI., is expected to be completed by the end of the calendar year.

Halo Genomics' technology addresses sequence-selective sample preparation. The company's HaloPlex technology combines the speed and specificity of PCR-based systems with the scalability and capture-size flexibility of solution-based hybridization formats, thus eliminating the need for library preparation.

HaloPlex technology is expected to complement Agilent's SureSelect target enrichment platform by providing a high-performance solution for small capture sizes. The speed of the technology reportedly addresses the needs of the desktop sequencing market and clinical sequencing space.

"Halo Genomics' unique technology and talented R&D team will expand Agilent's solutions for emerging sequencing applications and accelerate our entry into the rapidly growing next-gen clinical sequencing market," says Gustavo Salem, vp and GM of Agilent's biological systems division within the life sciences group.

BioSystem Development currently supplies Agilent's automation solutions business with AssayMAP cartridges used in conjunction with Agilent's Bravo liquid-handling platform for protein purification and characterization workflows. The combination reportedly enables chromatographic separation with precision flow control.

"We are excited about bringing BioSystem Development, a valued partner, into Agilent," says Fred Strohmeier, vp and GM of Agilent's liquid phase analysis division within the company's life sciences group. "BioSystem Development's innovative and versatile microchromatography technology and the team's applications expertise will help Agilent expand its capabilities as a sample-prep provider for the life sciences market."

The AssayMAP platform can be leveraged for bioprocess development, biomarker identification and analysis, as well as a variety of other life science research applications, according to Agilent.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Invests $80M in Lasergen
Company has announced that it has invested $80 million in Lasergen, with innovative next-generation sequencing technology for clinical applications.
Friday, March 11, 2016
Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent Recognizes Australian Genome Research Facility as Certified Service Provider
Nonprofit organization offers scientists access to leading-edge technologies.
Saturday, October 31, 2015
Agilent Announces New CEO Mike McMullen
McMullen elected as chief executive officer by Company’s board of directors.
Thursday, March 19, 2015
Agilent Names Alacris Theranostics as Certified Provider of Target Enrichment Services
Customers receive consistent data quality, reproducibility and reliability.
Saturday, January 17, 2015
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent Names Massachusetts Eye and Ear Infirmary as Certified Service Provider for NGS and aCGH Solutions
MEEI's Department of Ophthalmology Ocular Genomics Institute is working to harness the power of genomics and gene therapy to advance the knowledge and treatment of blinding eye diseases.
Thursday, October 24, 2013
Agilent Technologies Teams with University of Liverpool's Centre for Genomic Research
Centre for Genomic Research has become the UK's first Certified Service Provider for the Agilent SureSelect Target Enrichment System for next-generation sequencing.
Wednesday, August 08, 2012
Agilent Names University of Liverpool’s CGR as Certified Service Provider
CGR achieves certified status for Agilent SureSelect target enrichment system for next-generation sequencing.
Monday, July 23, 2012
Agilent Technologies and FDA Collaborate to Improve Testing for Salmonella
Project also seeks to develop better tools to test truth of seafood labels.
Monday, March 26, 2012
Agilent Technologies’ Exome Target-Enrichment System to Analyze 1,500 Samples in Erasmus Genetic Population Study
Erasmus Medical Center, Rotterdam, Netherlands, has selected the Agilent SureSelect XT Human All Exon target enrichment system along with the Agilent Bravo automated liquid-handling platform as part to identify genetic risk factors for some complex genetic disorders.
Thursday, March 08, 2012
Agilent Technologies and BGI to Collaborate
Companies announce a collaborative effort to develop methodologies designated for next-generation genome-wide association studies. The methodologies will assist scientists pursuing disease and drug research.
Wednesday, February 29, 2012
Scientific News
Five New Breast Cancer Genes Found
Discovery of mutations paves the way for personalised treatment of breast cancer.
New Neurodevelopmental Syndrome Identified
Study pinpoints underlying genetic mutations, raising hopes for targeted therapies.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Gene Behind Rare Childhood Syndrome Identified
Online activism by one patient’s mother spurred research collaboration which led to the identification of a new genetic syndrome.
Resilience Project Identifies Rare Unaffected Individuals
Researchers from Mount Sinai and Sage Bionetworks report analysis of nearly 600,000 genomes for resilience project.
Rare DNA Will Have Nowhere To Hide
Two National Institutes of Health grants back Rice University effort to develop new diagnostics.
Virus Causing Tilapia Die-Offs Identified
Discovery of the virus causing Tilapia die-offs in Israel and Ecuador points the way to protecting a fish that feeds multitudes.
Children With Cancer To Get New Gene Test
Pilot study will sequence 81 cancer genes in children’s tumours to help personalise cancer treatment.
How The Bat Got Its Wings
Finding may provide clues to human limb development and malformations.
Lupus Study Shows Precision Medicine’s Potential to Define the Genetics of Autoimmune Disease
Researchers at UT Southwestern have used next-generation DNA sequencing technology to identify more than 1,000 gene variants that affect susceptibility to SLE.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!